Amneal announces u.s. fda filing acceptance of new drug application for ipx203 for the treatment of parkinson's disease

Bridgewater, n.j.--( business wire )--amneal pharmaceuticals, inc. (nyse: amrx) today announced the u.s. food and drug administration (fda) has accepted for review the new drug application (nda) for ipx203 for the treatment of parkinson's disease (pd). ipx203 is a novel, oral formulation of carbidopa/levodopa (cd/ld) extended-release capsules.
AMRX Ratings Summary
AMRX Quant Ranking